49
Views
0
CrossRef citations to date
0
Altmetric
Case Reports

Subcutaneous phaeohyphomycotic cyst caused by Pyrenochaeta romeroi

, , , , , , , & show all
Pages 763-768 | Received 17 Aug 2009, Accepted 26 Oct 2009, Published online: 08 Jan 2010
 

Abstract

Pyrenochaeta romeroi is a rare agent of chronic, suppurative subcutaneous infections which ultimately lead to mycetoma. It has only rarely been reported from deep, non-mycetomatous infections. We describe a case of a subcutaneous phaeohyphomycotic cyst in a 45-year-old Indian female who suffered from verrucous plaque and a swelling (30 mm in diameter) on the right forearm that gradually increased in size over a period of 3 months. Direct microscopic examination with 10% KOH and histopathological investigation of exudates revealed septate hyphae without granules, the hallmark of mycetoma. The lesion appeared to be a subcutaneous phaeohyphomycotic cyst caused by P. romeroi. The suspected agent was recovered in culture, identified on the basis of morphologic features and its identification confirmed by sequencing of the internal transcribed spacer regions of rDNA. Treatment consisted of surgical excising of the cyst without any antifungal therapy. There was no relapse during a one-year follow-up and the patient was successfully cured. In vitro antifungal susceptibility tests demonstrated that itraconazole (0.5 μg/ml), isavuconazole (0.125 μg/ml) and posaconazole (0.5 μg/ml) had potent activity against this isolate of P. romeroi. High MICs were found with amphotericin B (4 μg/ml), fluconazole (>64 μg/ ml), voriconazole (4 μg/ml) and caspofungin (8 μg/ml). However, their clinical effectiveness in the treatment of P. romeroi infections remains to be evaluated.

Acknowledgements

This study was supported by a grant (No. 13081) to H. Badali from the Ministry of Health and Medical Education of the Islamic Republic of Iran and the School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.

Declaration of interest: J. F. G. M. Meis received grants form Astellas, Merck, Basilea and Schering-Plough. He has been a consultant to Basilea, Merck and Schering-Plough and received speaker's fees from Merck, Pfizer, Schering-Plough and Janssen Pharmaceutica. All other authors: no potential conflicts of interest. The authors alone are responsible for the content and writing of the paper.

This paper was first publisehd online on Early Online on 10 December 2009.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.